ClinicalTrials.gg
CompletedNCT05254548Updated May 4, 2022

A Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on What the Body Does to Flurbiprofen, Omeprazole, Midazolam in Healthy Subjects

A Phase 1 interventional study of ACT-539313 and Flurbiprofen in Healthy, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Germany. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-04.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

A study to investigate the effect of single and repeated oral doses of ACT-539313 on what the body does to flurbiprofen, omeprazole, midazolam in healthy participants.

Read the detailed description

A screening evaluation will be performed within 3 to 28 days (or within 10 to 28 days for women of childbearing potential) before first study treatment administration. Prior to any screening assessment, participants must sign the informed consent form.

Eligibility will be based on the results of the Screening and Day -1 assessments.

The participants will be confined to the study site from the morning of Day -1 until the morning of Day 2, from the morning of Day 7 until the morning of Day 9 and from the morning of Day 14 until the morning of Day 16. Participants will return to the study site for the End of Study examination on Day 17.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in a language understandable to the participant prior to any study-mandated procedure.
  • Healthy male or female subjects aged between 18 and 45 years (inclusive) at Screening.
  • of 18.5 to 28.0 kg/m2 (inclusive) at Screening.
  • Women of must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1. They must consistently and correctly use (from Screening, during the entire study, and for at least 30 days after study treatment intake) a highly effective method of with a failure rate of \< 1% per year, be sexually inactive, or have a vasectomized partner. If a hormonal contraceptive is used, it must have been initiated at least 1 month before treatment administration.
  • Women of non-childbearing potential, i.e., (defined as 12 consecutive months with no menses without an alternative medical cause, confirmed by a FSH test), with previous bilateral salpingectomy, bilateral salpingo-oophorectomy or hysterectomy, or with premature ovarian failure (confirmed by a specialist), XY genotype, Turner syndrome, uterine agenesis.
  • 12-lead (including : \< 450 milliseconds [for males] and \< 470 milliseconds [for females] without abnormalities, measured after 5 min in the supine position at Screening and on Day -1.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
  • findings in clinical laboratory tests (hematology, clinical chemistry, and urinalysis, i.e. outside the reference ranges (\< 0.9 lower limit of normal and > 1.1 ; except for relevant hepatic parameters [ (ALT), Aspartate Aminotransferase Test (AST), ] which must not exceed the upper limit of normal), at Screening and on Day -1.
  • History of major medical or surgical disorders which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment(s) (appendectomy and herniotomy allowed, cholecystectomy not allowed).
  • Acute, ongoing, recurrent, or chronic systemic disease with the ability to interfere with the evaluation of the study results.
  • Prior history of severe respiratory failure, acute respiratory depression, or sleep apnea.
  • Prior history of peptic ulcer disease and/or gastrointestinal bleeding.
  • Prior history of asthma, urticaria, or other allergic type reactions after taking acetylsalicylic acid or other NSAIDs.
  • History of cardiovascular thrombotic events (including myocardial infarction and stroke) and coronary artery bypass graft surgery.
  • Participation in a clinical study involving study treatment administered within 3 months (or 5 t 1/2 of the study treatment administered [whichever is longer]) prior to screening or in more than 4 clinical studies within 1 year prior to Screening.
  • Previous treatment with any prescribed medications (including vaccines) or over-the-counter (OTC) medications (including herbal medicines such as St. John's Wort, homeopathic preparations, vitamins, and minerals; with the exception of ibuprofen [1200 mg/day] or paracetamol [up to 1500 mg/day] up until Day -1) within 3 weeks (or 5 t1/2 [whichever is longer]) prior to first study treatment administration.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    ACT-539313 with or without a standard combination (probe substrate)

    Treatment arm has 4 in-house treatment periods. In Treatment Period 1, participants will receive a single oral dose of the standardized combination (probe substrate: containing flurbiprofen \[50 mg\], midazolam \[2 mg\] and omeprazole 20 \[mg\]) on Day 1. Participants will be discharged from the study site on Day 2 and will be re-admitted on Day 7. In Treatment Period 2 (morning of Day 8) a first oral dose of 100 mg ACT-539313 will be administered. One hour later a single oral dose of the probe substrate will be administered. In the evening of Day 8, a second oral dose of 100 mg ACT-539313 will be administered. During Treatment Period 3 (morning of Day 9, ending on the evening of Day 14) oral doses of 100 mg ACT-539313 will be administered in the morning and evening. In Treatment Period 4 (Day 15), a single oral dose of 100 mg ACT-539313 together with the probe substrate will be administered. The participants will receive the last dose of ACT-539313 in the evening of Day 15.

    Drug: ACT-539313 · Drug: Flurbiprofen · Drug: Omeprazole · Drug: Midazolam

Interventions

  • DrugACT-539313

    100 mg ACT-539313 (hard capsules) will be administered twice per day in period 2 (morning and evening of Day 8), period 3 (morning and evening of Day 9 to 14) and period 4 (morning and evening of Day 15).

  • One daily dose of flurbiprofen 50 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).

  • A single dose of omeprazole 20 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).

  • A single dose of midazolam 2 mg will be administered in period 1 (morning of Day 1), period 2 (morning of Day 8), and period 4 (morning of Day 15).

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax) of each probe substrate: flurbiprofen, midazolam and omeprazole.

    In periods 1, 2 and 4 the plasma pharmacokinetic parameters of flurbiprofen, omeprazole, and midazolam will be derived by non-compartmental analysis of the plasma concentration-time profiles. Plasma pharmacokinetic samples will be collected at multiple predefined time points to analyze probe substrate: flurbiprofen, midazolam and omeprazole concentrations.

    Time frame: Pre-dose through to 24 hours post-dose.

  2. Time to reach Cmax (tmax) of each probe substrate: flurbiprofen, midazolam and omeprazole.

    In periods 1, 2 and 4 the plasma pharmacokinetic parameters of flurbiprofen, omeprazole, and midazolam will be derived by non-compartmental analysis of the plasma concentration-time profiles. Plasma pharmacokinetic samples will be collected at multiple predefined time points to analyze probe substrate: flurbiprofen, midazolam and omeprazole concentrations.

    Time frame: Pre-dose through to 24 hours post-dose.

  3. The area under the plasma concentration-time curve from zero to 24 hours (AUC0-24) of flurbiprofen, midazolam and omeprazole.

    In periods 1, 2 and 4 the plasma pharmacokinetic parameters of flurbiprofen, omeprazole, and midazolam will be derived by non-compartmental analysis of the plasma concentration-time profiles. Plasma pharmacokinetic samples will be collected at multiple predefined time points to analyze probe substrate: flurbiprofen, midazolam and omeprazole concentrations.

    Time frame: Pre-dose through to 24 hours post-dose.

  4. The terminal elimination half-life (t½) of each probe substrate: flurbiprofen, midazolam and omeprazole.

    In periods 1, 2 and 4 the plasma pharmacokinetic parameters of flurbiprofen, omeprazole, and midazolam will be derived by non-compartmental analysis of the plasma concentration-time profiles. Plasma pharmacokinetic samples will be collected at multiple predefined time points to analyze probe substrate: flurbiprofen, midazolam and omeprazole concentrations.

    Time frame: Pre-dose through to 24 hours post-dose.

  5. ACT-539313 trough plasma concentrations (Ctrough)

    In periods 2, 3 and 4 the plasma pharmacokinetic parameters of ACT-539313 will be measured prior to the next dose being administered in the morning.

    Time frame: Pre-dose through to 10 days after first dose.

Other outcomes

  1. Treatment-emergent adverse events

    All adverse events will be collected, however, adverse events occurring during the in-between period (from end of period 1 up to first study treatment administration in period 2, are not considered as treatment-emergent adverse events.

    Time frame: From study treatment administration on Day 1 up to last assessment at End of Study (Day 17).

  2. Maximum plasma concentration (Cmax) of ACT-539313

    In periods 2 (Day 8 and 9) and period 4 (Day 15, 16 and 17) the plasma pharmacokinetic parameters of ACT-539313 will be derived by non-compartmental analysis of the plasma concentration-time profiles. Cmax will be analyzed in periods 2 and 4 with the administration of probe substrate. In period 4 the Cmax will be determined after steady state ACT-539313 concentrations have been reached.

    Time frame: Pre-dose through to 24 hours post-dose.

  3. Time to reach Cmax (tmax) of ACT-539313

    In periods 2 (Day 8 and 9) and period 4 (Day 15, 16 and 17) the plasma pharmacokinetic parameters of ACT-539313 will be derived by non-compartmental analysis of the plasma concentration-time profiles. tmax will be analyzed in periods 2 and 4 with the administration of probe substrate. In period 4 the tmax will be determined after steady state ACT-539313 concentrations have been reached.

    Time frame: Pre-dose through to 24 hours after first dose.

  4. Area under the plasma concentration-time curve [AUC(tau)] of ACT-539313

    In periods 2 (Day 8 and 9), period 3 (Day 10 to Day 15) and period 4 (Day 15, 16 and 17) plasma pharmacokinetic samples will be collected at multiple predefined time points to analyze ACT-539313 concentrations. AUC(tau) will be calculated according to the linear trapezoidal rule using the measured concentration-time values above the limit of quantification.

    Time frame: Pre-dose through to 240 hours after first dose.

07

Study locations

1 site
  • CRS Clinical Research Services Berlin GmbH
    Berlin, 13353, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Apr 2022, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2022
First posted
Feb 24, 2022
StartActual
Feb 18, 2022
Primary completionActual
Apr 13, 2022
CompletionActual
Apr 13, 2022
Last update
May 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05254548
Responsible party
Sponsor
First posted
Feb 24, 2022
Start date
Feb 18, 2022
Primary completion
Apr 13, 2022
Completion
Apr 13, 2022
Last update
May 4, 2022

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flurbiprofen

Start the discussion